10x Genomics Launches Next Generation Immune Profiling Product to Combat COVID-19

Delivers major improvements for discoveries in immunology, oncology, autoimmunity, and infectious diseases

Pleasanton, California, UNITED STATES

PLEASANTON, Calif., July 14, 2020 (GLOBE NEWSWIRE) -- 10x Genomics (Nasdaq: TXG) strengthened the research toolkit of scientists around the globe today with the launch of its Chromium Single Cell Immune Profiling v2 product. The new product extends the capabilities of the original version, supporting fundamental breakthroughs in immunology, oncology, autoimmunity, inflammation, transplant biology, and infectious diseases. It also significantly builds on the existing product that is being used by researchers to understand COVID-19 to advance science for the development of vaccines, antiviral drugs and clinical treatments related to the SARS-CoV-2 viral infection.  

The new Chromium Single Cell Immune Profiling v2 product provides a comprehensive approach to simultaneously examine cellular heterogeneity of the immune system, T and B cell repertoire diversity, and antigen specificity at single cell resolution. Researchers can profile thousands of genes and hundreds of cell surface proteins, cell by cell and at scale, with enhanced sensitivity, resolution, and sequencing quality. The latest product offers up to a 60 percent increase in gene detection sensitivity, allowing users greater flexibility in reducing sequencing costs without a loss in gene diversity or accessing rare gene transcripts without an increase in cost.  

Using the Chromium Single Cell Immune Profiling v2 product, researchers can:

  • Characterize adaptive and innate immune cell diversity
  • Identify and characterize rare cell types and biomarkers
  • Analyze tissue microenvironment, disease progression, and drug immune response
  • Perform large-scale antibody and TCR discovery for novel antigens
  • Characterize immune responses to infection by measuring clonal expansions and immune cell phenotypes
  • Focus on relevant genes and pathways with predesigned gene expression panels for immunology, oncology, and drug discovery, or design a fully custom panel

“With the number of coronavirus cases expected to reach 100,000 a day in the US alone, it is critical that we get the right products into the hands of scientists as soon as possible,” said Ben Hindson, co-founder and chief scientific officer of 10x Genomics. “Our new product adds a powerful tool to our customers’ arsenal for combating COVID-19 and other deadly diseases, and is a testimony to our very rich product pipeline.”

10x Genomics has supported more than 300 customers in academic, governmental, biotechnology, and pharmaceutical organizations around the world who are working to understand SARS-CoV-2 and manage COVID-19. These include Vanderbilt University Medical Center, the Charite Hospital Berlin, Singapore-based Proteona, and the Biomedical Pioneering Innovation Center (BIOPIC) at Peking University. Many 10x Genomics customers have placed the Chromium Controller instrument into biosafety level 2+ and 3 facilities, where its products can be used to support research on acutely infected patient or animal model samples. 

Over a dozen peer-reviewed papers have been published that feature the use of 10x Genomics Chromium Single Cell Immune Profiling product in COVID-19 research, including studies to better understand the precise cells in which organs and tissues could become infected (Nature Medicine); immune system responses to COVID-19 infection across patients with varying severities of disease (Nature Cell Discovery, Nature Medicine); and ways neutralizing antibodies could be used to effectively block virus entry into host cells (Cell). 

The Chromium Single Cell Immune Profiling v2 product is available for pre-order today and is expected to ship at the end of the month. 

About 10x Genomics
10x Genomics is a life science technology company building products to interrogate, understand and master biology to advance human health. The company’s integrated solutions include instruments, consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. 10x Genomics products have been adopted by researchers around the world including 97 of the top 100 global research institutions and 19 of the top 20 global pharmaceutical companies, and have been cited in over 1,000 research papers on discoveries ranging from oncology to immunology and neuroscience. The company's patent portfolio comprises more than 740 issued patents and patent applications.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negatives of these terms or variations of them or similar terminology.  These forward-looking statements include statements regarding 10x Genomics, Inc.’s partnership activities, which involve risks and uncertainties that could cause 10x Genomics, Inc.’s actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on management’s current expectations, forecasts, beliefs, assumptions and information currently available to management, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect 10x Genomics, Inc.’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents 10x Genomics, Inc. files with the Securities and Exchange Commission from time to time. The forward-looking statements in this press release are based on information available to 10x Genomics, Inc. as of the date hereof, and 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing 10x Genomics, Inc.’s views as of any date subsequent to the date of this press release.

Disclosure Information
10x Genomics uses filings with the Securities and Exchange Commission, its website (www.10xgenomics.com), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.